A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.

drug protocol number
MS200527ˍ0082
drug sponsor
Merck
drug study
Evobrutinib
drug trial site
King Faisal Specialist Hospital and Research Center (Jeddah)
drug status
Ongoing
drug phase